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Charcot–Marie–Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies charac-
terizedbyaphenotype that ismore severe in theupper extremities.Wepreviously implicatedmutations in thegeneencodingglycyl-tRNA
synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is amember of the family of aminoacyl-tRNA synthetases responsible for
charging tRNA with cognate amino acids; GARS ligates glycine to tRNAGly. Here, we present functional analyses of disease-associated
GARSmutations and show that there are not any significantmutation-associated changes inGARS expression levels; that themajority of
identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in
neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-
charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projec-
tions of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the
recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together,
these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons.
Key words: Charcot–Marie–Tooth disease; spinal muscular atrophy; peripheral neuropathy; axonopathy; tRNA synthetase; axonal
translation
Introduction
Charcot–Marie–Tooth (CMT) disease comprises a heteroge-
neous group of inherited neurodegenerative disorders that affect
the peripheral nerve. Although the overall presentation varies,
the general clinical features of CMT include muscular weakness
and atrophy in the distal extremities. An estimated 1 in 2500
individuals are affected with CMT, making it the most common
inherited peripheral neuropathy (Skre, 1974). CMT can be di-
vided into two classes based on motor nerve conduction veloci-
ties (MNCVs) (Dyck and Lambert, 1968). Patients with CMT
type 1 (CMT1) have decreasedMNCVs and evidence of demyeli-
nating axons, whereas patients with CMT type 2 (CMT2) have
normal MNCVs and no demyelination; as such, CMT1 is classi-
fied as a demyelinating neuropathy and CMT2 as an axonal
neuropathy.
Our previous genetic studies implicated glycyl-tRNA syn-
thetase gene (GARS) mutations in two neurodegenerative dis-
eases: CMT2D and distal spinal muscular atrophy type V
(dSMA-V) (Antonellis et al., 2003). These two diseases are con-
sidered axonal neuropathies based on electrophysiological fea-
tures and are distinguished by sensory loss seen in CMT2D but
not dSMA-V patients (Antonellis et al., 2003; Sivakumar et al.,
2005). Furthermore, CMT2D and dSMA-V patients tend to have
more severe symptoms in the upper compared with lower ex-
tremities (Christodoulou et al., 1995; Ionasescu et al., 1996; Sam-
buughin et al., 1998; Antonellis et al., 2003; Sivakumar et al.,
2005).
One possibility is that axonal neuropathies are caused by de-
fects specific to the nerve cell axon. This notion is supported by
the identification of other CMT-associated mutations in genes
encoding proteins with a role in axonal transport or cytoskeleton
maintenance (Mersiyanova et al., 2000; Zhao et al., 2001; Ver-
hoeven et al., 2003; Evgrafov et al., 2004). GARS, however, is a
ubiquitously expressed 2 homodimer responsible for charging
tRNA molecules with glycine (Freist et al., 1996); this enzyme is
essential for protein synthesis in all cells and tissues. Therefore, it
is of interest to understand how defects in GARS can lead to the
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limited phenotype of peripheral axonal neuropathy that is more
pronounced in the upper extremities.
In light of the identification of disease-associatedmutations in
multiple sites andwithin functional domains of the encoded pro-
tein, we hypothesized that GARS mutations cause impaired en-
zyme function and that peripheral nerve axons may be more
sensitive than other cell types to impaired tRNA charging (An-
tonellis et al., 2003). Interestingly, this hypothesis is supported by
the recent identification and characterization of YARS (tyrosyl-
tRNA synthetase gene) mutations in patients with dominant in-
termediate CMT (Jordanova et al., 2006).Here, we describe func-
tional analyses of disease-associated GARS mutations and
present data that suggest an important role for tRNA-charging
enzymes in the maintenance of axonal health.
Materials andMethods
GARS protein expression and purification. Wild-type GARS protein was
expressed after cloning into pET21a() (Novagen, Madison, WI) using
Escherichia coli BL21-CodonPlus(DE3)-RIL cells (Stratagene, La Jolla,
CA) and then purified under denaturing conditions using the ProBond
purification system (Invitrogen, Carlsbad, CA) according to the instruc-
tions of the manufacturer. Nine 1 ml fractions were eluted from the
extraction column and concentrated onMicroconYM-10 columns (Mil-
lipore, Bedford, MA). The majority of the GARS protein was found to
reside in the second 1 ml fraction, as assessed by Western blot analysis
using an anti-6XHis antibody (data not shown).
Northern blot analysis. Total RNAwas isolated from cultured lympho-
blastoid cell lines using the RNeasy Mini kit (Qiagen, Valencia, CA).
Purified RNA (10 g) from each sample was loaded on 1% agarose gels,
electrophoresed at 90 V for 4 h, and transferred to Hybond-N nylon
membranes (GE Healthcare, Piscataway, NJ) in 0.01N NaOH/3 M NaCl.
A PCR product spanning nucleotides 1485–2200 of the GARS mRNA
(GenBank accession number NM_002047) was generated from a full-
length cDNA clone (IMAGE 4109682) and radiolabeled with [ 32P]dCTP
using Ready-To-GoDNA labeling beads (GEHealthcare). After removal
of unincorporated nucleotides, the probe was hybridized to the above
Northern blots using ExpressHyb hybridization solution (Clontech Lab-
oratories, Palo Alto, CA) at 37°C for 1 h. Membranes were washed twice
in 2 SSC/0.1% SDS and then twice in 0.1 SSC/0.1% SDS, in each case
for 40 min at room temperature. Hybridization results were captured
using a Fujifilm FLA-5000 phosphoimager (Fujifilm, Stamford, CT). A
probe for the -actin gene was prepared and used in the samemanner to
assess differences in the total amount of RNA analyzed.
Real-time PCR. Allele-specific PCR primers for the wild-type (5-
GCCTGGAGGAAACATGCCTG-3) and G240R (5-GCCTGGAGG-
AAACATGCCTC-3) GARS mRNA were used in conjunction with a
common reverse primer (5-GAAGGTCTGCCACATTCTGG-3). RNA
was extracted as above, and reverse transcription was performed using
poly-dT primers. Real-time PCRwas performed using an iCycler iQ Real
Time PCR Detection System (Bio-Rad, Hercules, CA) and measured by
Syber green incorporation using the SYBR GreenER qPCR Supermix
(Invitrogen). Allele copy number was assessed by including a vector of
known copy number that contained either the wild-type or G240RGARS
cDNA (see below). In parallel, a PCR product was generated from the
-actin gene to correct for variation in the generation of reverse tran-
scription products. Similar analyses were performed to detect yeast
glycyl-tRNA synthetase gene (GRS1) alleles. All primer sequences are
available on request.
Western blot analyses.Cultured human lymphoblastoid cells were har-
vested and resuspended in 37.5 l of lysis solution containing 10 mM
Tris-HCl/1mMEDTA/50mMNaCl/1 protein-reducing agent (Invitro-
gen) and 12.5 l of loading buffer containing SDS (Invitrogen). After
incubation at 95°C for 5 min, the total protein lysate derived from
50,000 cells was electrophoresed on 4–12% Bis-Tris gels (Invitrogen)
at 125 V for 100 min in running buffer containing SDS (Invitrogen).
Samples were then electroblotted onto nitrocellulose membranes at 25 V
for 100 min in NuPAGE transfer buffer (Invitrogen). Membranes were
blocked in 1 PBS/0.05% Tween 20/5% nonfat dry milk for 18 h at 4°C
and then incubated with a 1:5000 dilution of 1 g/l anti-GARS (see
below), 1 g/l anti-6XHis (Invitrogen), or 1 g/l anti-actin (Sigma,
St. Louis, MO) antibody in blocking solution for 1 h at room tempera-
ture. Membranes were washed three times in 1 PBS plus 0.05% Tween
20, incubated with a secondary antibody conjugated to horseradish per-
oxidase [donkey anti-rabbit IgG (GE Healthcare) for anti-GARS and
anti-actin, and rat anti-mouse IgG (Zymed Laboratories, South San
Francisco, CA) for anti-6XHis] for 1 h at room temperature, washed
three times as described above, and finally incubated with DAB substrate
(RocheDiagnostics, Basel, Switzerland), according to themanufacturer’s
instructions. Note that purified recombinant humanGARSwas analyzed
in a similar manner. Optical densities of bands on Western blots were
determined using ImageJ software (http://rsb.info.nih.gov/ij/), with
background densities subtracted from each measurement. Band-
intensity ratios were determined by dividing the optical densities of
GARS-specific bands by the optical densities of corresponding actin-
specific bands.
Custom rabbit anti-GARS antibodies were generated by Zymed Lab-
oratories using peptides corresponding to four regions of the human
GARS protein (amino acid positions 18–31, 302–313, 633–646, and
673–685 in GenBank NP_002038). Peptide-blocking controls were per-
formed using an 250-fold excess of the antigenic peptide (Zymed
Laboratories).
Construction of GARS- and GRS1-containing expression vectors. The
humanGARS open reading frame was PCR amplified using a full-length
cDNA clone (IMAGE 4109682; GenBank accession number BC007755)
as a template. The PCR primers contained flanking NdeI (forward) and
XhoI (reverse) restriction sites to allow cloning into the pET-21a()
expression vector (Novagen) in frame with a C-terminal 6XHis tag. Al-
ternatively, the PCR primers contained flanking PstI (forward) and SmaI
(reverse) restriction sites to allow cloning into the pEGFP-N2 expression
vector (BD Biosciences, Palo Alto, CA) in frame with a C-terminal en-
hanced green fluorescent protein (EGFP) tag. The Saccharomyces cerevi-
siae GRS1 locus (including the open reading frame and 620 bp of up-
stream sequence) was PCR amplified directly from yeast genomic DNA.
The PCR primers contained flankingNotI restriction sites to allow clon-
ing into the NotI site of the yeast vector pRS315 (Sikorski and Hieter,
1989). After suitable restriction enzyme digestion, the PCR-amplified
GARS- or GRS1-containing fragments were cloned into the appropriate
vector using standard methods. PCR analyses of the resulting bacterial
colonies were used to confirm the presence of a GARS- or GRS1-
containing insert. Subsequent site-directed mutagenesis was performed
using the QuikChange site-directed mutagenesis kit (Stratagene) and
appropriatemutation-bearing oligonucleotides. AnXhoI fragment of the
resulting vectors was shuttled into pYES2 (Invitrogen) for overexpres-
sion in yeast. All constructs were sequenced to confirm the presence of
the designed mutation and the absence of PCR-induced errors.
Yeast growth assays. The yeast strain RJT3/II-1 [his3200, leu21,
ura3-52, grs1::HIS3; maintained by a GRS1-containing centromere vec-
tor bearingURA3 (Turner et al., 2000)] is devoid of an endogenousGRS1
locus, which was deleted via a recombination with a HIS3-containing
cassette containing sequences that flank GRS1 in the yeast genome. This
strain was transformed with pRS315 constructs containing wild-type or
mutant GRS1 (described above) or no insert. Briefly, lithium acetate
transformations (Green et al., 1999)were performed at 30°Cusing 200ng
of plasmidDNA. Transformation reactionswere plated on yeastmedium
lacking uracil and leucine, and the resulting colonies were tested by PCR
using primers specific to GRS1 and pRS315. For each transformation,
four colonies found to carry the appropriate construct were selected for
additional analysis. Each colony was then inoculated into 2 ml of yeast
medium lacking uracil and leucine and incubated shaking at 30°C for
18 h. Culture dilutions (1:1, 1:5, 1:10, and 1:125) were generated in yeast
extract, peptone, and dextrose (YPD) medium (Qbiogene, Irvine, CA),
spotted on growthmediumcontaining 0.1%5-fluoroorotic acid (5-FOA;
Teknova, Hollister, CA), and incubated at 30°C for 2 d. Growth was
assessed by visual inspection. To generate growth curves, surviving yeast
colonies were inoculated in selective medium and incubated shaking
overnight at 30°C.Dilutions (1:25) were then generated in YPDmedium,
10398 • J. Neurosci., October 11, 2006 • 26(41):10397–10406 Antonellis et al. • GARS and Peripheral Axon Health
with the new cultures incubated shaking at 30°C. The OD660 of 1 ml
aliquots was thenmeasured at 0, 2, 3, 4, and 5 h using a BeckmanDU 650
spectrophotometer (Beckman Coulter, Fullerton, CA). The percentage
increase in growthwas determined by dividing each of the fourmeasured
OD660 values by the initial OD660 value. Curves were generated using the
average of the data obtained with the four separate PCR-positive colo-
nies. Similar studies on strains carrying two copies of GRS1 were per-
formed on growthmedium containing glycerol or galactose for detecting
mitochondrial mutations and dominant-negative effects, respectively.
Cell culture and differentiation. 293T cells, COS7 cells, and the mouse
motor neuron cell lineMN-1 (Salazar-Grueso et al., 1991) were cultured
in DMEM growth medium (Invitrogen) containing 10% fetal bovine
serum, 50 U/ml penicillin, 50 g/ml streptomycin, and 2 mM
L-glutamine. The humanneuroblastoma cell line SH-SY5Y (Biedler et al.,
1978; Ross et al., 1983) was cultured in DMEM/F-12 medium (Invitro-
gen) containing 10% fetal bovine serum, 50 mM HEPES, 50 U/ml peni-
cillin, 50 g/ml streptomycin, and 2 mM L-glutamine. All cells were
grown at 37°C in 5% CO2. For cell differentiation, transfection studies,
and antibody staining, cultured cells were counted with a hemacytome-
ter, and8.3 105 cells were placed into each well of a two-well culture
slide (BD Biosciences Discovery Labware, Bedford, MA) pretreated with
5g/cm2 entactin–collagen IV–laminin attachment matrix (Millipore).
MN-1 cells were differentiated by the addition of 2 nM glial cell line-
derived neurotrophic factor (GDNF) and 833 pM GDNF receptor -1
(GFR-1; both from R&D Systems, Minneapolis, MN) to the culture
medium and incubation for 48 h (Paratcha et al., 2001). SH-SY5Y cells
were differentiated by the addition of 10 M all-trans retinoic acid
(Sigma) to the culture medium and incubation for 6 d, with the medium
changed every 48 h (Sharma et al., 1999).
Transfection studies. pEGFP-N2 constructs encoding wild-type ormu-
tant GARS tagged with EGFP (described above) or no insert were trans-
fected into cells using the Lipofectamine 2000 reagent (Invitrogen)
according to the instructions of the manufac-
turer. For each reaction, 20l of Lipofectamine
2000 and 500 l of OptiMEM I minimal
growth medium (Invitrogen) were combined
and incubated at room temperature for 10min.
Purified plasmid DNA (2g) or the equivalent
volume of water (in the case of negative con-
trols) was diluted in 500 l of OptiMEM I,
combinedwith the above Lipofectamine–Opti-
MEM I mixture, and incubated at room tem-
perature for 20 min. The entire sample was
then added to a single well of a two-well culture
slide containing the desired cell line (see
above). After a 4 h incubation at 37°C, the me-
dium was aspirated, the slides were washed
with 1 PBS, and normal growth medium was
added. After a 24 h incubation at 37°C, cells
were washed with 1 PBS and then fixed in 4%
paraformaldehyde in 1 PBS at room temper-
ature for 30min. Finally, the slides werewashed
three times in 1 PBS and coated with Pro-
Long antifade reagent (Invitrogen, Eugene,
OR). To visualize mitochondria in COS7 cells,
cells were transfected with the pDsRed2–Mito
vector (BD Biosciences) as described above.
Antibody staining. Human SH-SY5Y cells
were cultured at 37°C for 6 d in differentiation
medium (see above) using two-well culture
slides (BD Biosciences Discovery Labware).
Cells were fixed in 4% paraformaldehyde, per-
meabilized in 0.2%Triton X-100 in 1 PBS for
5 min, washed in 1 PBS, and incubated in
blocking solution containing 10% normal goat
serum/1 PBS/0.05% sodium azide (Zymed
Laboratories) for 30 min. Cells were then incu-
bated in 10 g/ml anti-GARS673 in blocking
solution for 60 min. After three washes in 1
PBS, cells were incubated in goat anti-rabbit
IgG secondary antibody conjugated with FITC (Zymed Laboratories) for
60 min. After three washes in 1 PBS, cells were incubated in 300 nM
4,6-diamidino-2-phenylindole dihydrochloride (DAPI; Invitrogen) in
1 PBS for 5 min. Cells were washed three times in 1 PBS, the well
apparatus was removed, and slides were coated with ProLong antifade
reagent (Invitrogen). All incubation and wash steps were performed at
room temperature. To detect other cellular structures, cells were
costained with mouse anti-bovine -tubulin (1:50; Invitrogen), mouse
anti-human survival motor neuron (SMN) (1:100; BD Biosciences
Pharmingen, San Jose, CA), mouse anti-nucleolar antigen (1:30; Gene-
Tex, San Antonio, TX), or mouse anti-OxPhos complex IV (1:100; In-
vitrogen) followed by a goat anti-mouse IgG secondary antibody conju-
gated with tetramethylrhodamine isothiocyanate (Zymed Laboratories),
as described above.
Formalin-fixed, paraffin-embedded tissue sections were subjected to
two 10 min incubations in xylene, after which the slides were rinsed in a
series of 2 min ethanol washes (100, 95, and 80%) followed by a 5 min
rinse in deionized water. Slides were then placed in 50 ml conical tubes
containing 37.5 ml of target retrieval solution (DakoCytomation,
Carpinteria, CA), incubated in a 95°C water bath for 30 min, cooled at
room temperature for 20min, and rinsed three times in 1PBS for 5min
each. The resulting tissue sections were then stained with anti-GARS673
and DAPI, as described above. To visualize axons, sections were stained
with mouse anti-human phosphorylated neurofilament (1:320;
DakoCytomation).
Fluorescence microscopy and image collection.Microscopic images were
obtained using either a Zeiss model LSM 510 confocal fluorescence mi-
croscope (Zeiss, Oberkochen, Germany) or a Zeiss Axiovert 200M fluo-
rescence microscope (Zeiss) equipped with an ORCA-ER digital camera
(Hamamatsu Photonics, Hamamatsu, Japan) using Openlab image soft-
ware version 4.0.2 (Improvision, Lexington, MA).
Figure 1. Expression of mutant GARS. A, Total RNA was extracted from lymphoblastoid cell lines derived from unaffected
noncarriers (/) andCMT2D-affected carriers of theG240RGARSmutation (/G240R) and subjected toNorthernblot analysis.
Blots were hybridized with a GARS- or -actin-specific probe, as indicated. B, Real-time PCR was performed using reverse-
transcribed RNA from the cell lines described inA and allele-specific primers. Copy number of thewild-type (Wt) andG240R alleles
was measured by including known concentrations of control plasmids containing wild-type or G240R GARSmRNA. C, Real-time
PCR studies were performed similarly to those in B, except that primers specific for the-actin gene were included to assess the
efficiency of the reverse-transcription reactions. The ratio ofGARSmRNA to-actinmRNAwas then calculated.D, rhGARS–6XHis
was subjected toWestern blot analysis using an anti-GARS 673 or anti-6XHis antibody, as indicated. In two cases, the hybridization
was performed in the presence of excess 673–685 peptide. Similar analyses were performed with a total protein lysate from a
lymphoblastoid cell line of an unaffected noncarrier (/) using anti-GARS 673. E, Western blot analyses were performed with
total protein lysates of lymphoblastoid cell lines from unaffected noncarriers (/) and CMT2D-affected carriers of the G240R
GARSmutation (/G240R) using an anti-GARS 673 or anti-actin antibody, as indicated. F, The ratio of GARS to actin protein levels
was determined by dividing the optical density of each GARS-specific Western blot band with that of the corresponding actin-
specific band (e.g., as in E) using four independent Western blots. Error bars indicate SEM.
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Results
The G240RGARSmutation does not impair transcription
or translation
Weanalyzed lymphoblastoid cell lines fromCMT2Dpatients and
appropriate controls by Northern blot analyses to assess the rel-
ative levels of GARS mRNA. G240R heterozygotes (/G240R)
and noncarriers (/) express appropriately spliced GARS
mRNA (2.7 kb) at similar levels (Fig. 1A). To ensure that mu-
tant RNA is expressed and stable, we performed reverse
transcription-PCR and DNA sequencing with the RNA samples.
This revealed the presence of both wild-type and G240R GARS
alleles in the mRNA population of G240R heterozygotes (data
not shown), indicating that the G240R mutation does not reflect
a null allele. In addition, we performed reverse transcription and
allele-specific real-time PCRon the above samples to quantify the
levels of each GARS allele (Fig. 1B,C). This revealed that both
alleles are expressed, albeit with the G240R allele showing slightly
lower expression than the wild-type allele. Thus, the G240R mu-
tation does not cause a severe reduction inGARSmRNA levels in
lymphoblastoid cell lines.
We also performed Western blot analyses using a rabbit anti-
peptide antibody raised against residues 673–685 (anti-
GARS673) of the human GARS protein. When analyzing recom-
binant human GARS tagged with 6XHis (rhGARS–6XHis), anti-
GARS673 detects a similarly sized protein (slightly80 kDa) as an
anti-6XHis antibody (Fig. 1D). Factoring in the size of the 6XHis
tag, these data are consistent with the previously predicted mo-
lecular weight of humanGARS [between 77 and 80 kDa (Targoff,
1990; Hirakata et al., 1992; Williams et al., 1995)]. The 673–685
peptide abolishes detection of this band with anti-GARS673.
Western blot analysis of a total protein sample from a noncar-
rier (/) lymphoblastoid cell line with anti-GARS673 reveals a
protein80 kDa in size (Fig. 1D); once again, the 673–685 pep-
tide abolishes detection of this band. Interestingly, a smaller band
(60 kDa in size) is also detected by anti-GARS673 in approxi-
mately half of the analyses, and addition of the 673–685 peptide
also abolishes the detection of this band (data not shown). A
GARS variant with this molecular weight has not been described
(although the assessment of GARS size in lymphoblastoid cell
lines has not been reported previously). This smaller proteinmay
represent a novel GARS variant or a GARS-related protein with
an epitope similar to the 673–685 peptide. Visual inspection of
Western blots (Fig. 1E) and quantitative analysis of the optical
densities of GARS- and actin-specific bands (Fig. 1F) suggest that
lymphoblastoid cell lines from G240R heterozygotes (/G240R)
and noncarriers (/) express similar levels of the GARS pro-
tein. Thus, the G240R mutation does not lead to a severe reduc-
tion in GARS protein levels in lymphoblastoid cell lines.
MostGARSmutations modeled in yeast cause growth defects
We studied the effects of GARS mutations modeled in GRS1.
Specifically, GRS1 was mutagenized to create analogous versions
of five GARS mutations identified in CMT2D and dSMA-V pa-
tients (Table 1). For each of these mutations, the amino acid
affected by the human GARS mutation is identical in GRS1. The
various forms ofGRS1were generated in a yeast centromere vec-
tor bearingHIS3; each in turnwas transfected into the yeast strain
RJT3/II-1 (Turner et al., 2000). In this strain, the endogenous
GRS1 locus is deleted; however, because GRS1 is an essential
gene, this strain carries a yeast centromere vector-bearing wild-
type GRS1 and URA3 to maintain viability.
Haploid yeast carrying an inactive form ofGRS1would not be
expected to grow, becauseGRS1 is an essential gene (Turner et al.,
2000). To test the viability of yeast strains bearing GRS1 muta-
tions, we used 5-FOA treatment (Boeke et al., 1984) to eliminate
the URA3-containing vector (along with wild-type GRS1). Sub-
sequently, each strain was examined for growth and viability.
Three of themodeledGARSmutations (corresponding to human
mutations L129P, H418R, and G526R) show substantial reduc-
tions in yeast viability compared with wild-type GRS1 (Fig. 2A).
In contrast, two modeled GARS mutations (corresponding to
human mutations E71G and G240R) do not appear to have a
major effect on yeast viability. Because GRS1 (as well as GARS)
charges tRNA in both the cytoplasm and mitochondria (Shiba et
al., 1994; Turner et al., 2000), we tested the ability of strains
surviving 5-FOA treatment to grow on media containing glyc-
erol, which forces the use of mitochondria for ATP production.
This analysis did not reveal any growth defects associated with
GRS1mutations (data not shown).
GARS and GRS1 are predicted to exist as homodimers in vivo.
Thus, it is possible that the presence of a mutant subunit in the
homodimer ablates enzyme function by a dominant-negative
mechanism. To study this, we examined the growth of yeast
strains carrying two copies of the GRS1 gene. First, we analyzed
the growth of strains carrying two GRS1 alleles, both expressed
Table 1. Human GARSmutations modeled in the yeast ortholog GRS1
Human GARSmutationa Yeast GRS1mutationb
E71G E21G
L129P L79P
G240R G223R
H418R H402R
G526R G512R
aAmino acid coordinates correspond to the sequence in GenBank NP_002038.
bAmino acid coordinates correspond to the sequence in GenBank NP_009679.
Figure 2. Growth of yeast strains containingwild-type andmutant GRS1. A, Representative
cultures of the indicated yeast strainswere inoculatedandgrownonmediumcontaining5-FOA.
Each strain had been transfected previously with a vector containing no insert (pRS315), wild-
type (Wt) GRS1, or the indicated mutant form of GRS1 that modeled a human GARSmutation
(Table 1). B, Representative cultures of the indicated yeast strains were inoculated and grown
onmedium containing glucose. Each strain contains the wild-type GRS1-bearing maintenance
vector (see Materials and Methods for details) as well as a transformed vector expressing the
indicated GRS1 allele from the endogenous promoter. TheWt/pRS315 strain contained a trans-
formed vector without an insert. C, Similar experiment to that in B, except that strains were
grown onmedium containing glycerol.D, Representative cultures of the indicated strains were
inoculated and grown on medium containing galactose; each strain contained two copies of
GRS1, one wild-type copy expressed from the endogenous promoter and one expressing the
indicated allele from the GAL1 promoter.
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with the endogenous promoter and cultured inmedia containing
either glucose (Fig. 2B) or glycerol (Fig. 2C). In addition, we
performed allele-specific real-time PCR to ensure that bothGRS1
alleles were expressed at similar levels. These experiments were
successfully performed for three of the
mutant GRS1 forms (corresponding to hu-
man mutations G240R, H418R, and
G526R); ineachcase, themutantGRS1allele
was found to be expressed at a similar (or
higher) level as the wild-type allele (data not
shown). Next, we analyzed the growth of
strains carrying one GRS1 allele expressed
with theendogenouspromoterandasecond
allele overexpressed with the GAL1 pro-
moter by culturing in galactose-containing
media (Fig. 2D). These experiments did not
reveal mutation-associated impairment of
yeast cell growth, indicating thatGARSmu-
tations modeled in GRS1 do not cause a
dominant-negative mechanism in yeast
cells. Growth curve studies performed with
all of the same strains were consistent with
this conclusion (data not shown).
Endogenous GARS is associated with
granules in cultured neuron cells
The cellular and tissue distribution of
GARS has not been reported. To begin ex-
ploring the cellular localization of the en-
zyme, we studied endogenous GARS in
the human neuroblastoma cell line SH-
SY5Y, which can be differentiated with
retinoic acid to form long neurite projec-
tions (Sharma et al., 1999). Staining differ-
entiated SH-SY5Y cells with anti-
GARS673, anti--tubulin, and DAPI
revealed the presence of large GARS-
associated granules (or globules) in the
nucleus and smaller GARS-associated
granules in the cell body and neurite pro-
jections (Fig. 3A–C).
SMN is mutated in juvenile-onset spi-
nal muscular atrophy and encodes an
RNA-binding protein that localizes to
gems [Gemini of the coiled bodies (Liu
and Dreyfuss, 1996)] in cell nuclei. We
stained differentiated SH-SY5Y cells with
anti-GARS673, anti-SMN, and DAPI, and
found no evidence for colocalization of
the GARS and SMN proteins (Fig. 3D–F).
Methionine-tRNA synthetase (MARS)
was previously localized to the nucleolus
of five cell lines and implicated in ribo-
somal RNA synthesis (Ko et al., 2000).We
stained differentiated SH-SY5Y cells with
anti-GARS673, anti-nucleolar antigen, and
DAPI and found that GARS also localizes
to the nucleolus (Fig. 3G–I). These novel
findings were replicated in non-neuronal
cells (293T and COS7) (data not shown),
indicating that the cellular localizations of
these proteins are not unique to neurons.
Because GARS is known to function in
both the cytoplasm andmitochondria (Shiba et al., 1994; Turner
et al., 2000), we tested whether the GARS-associated granules
represent mitochondria. Two cell populations were prepared for
this: (1) differentiated SH-SY5Y cells stained with anti-OxPhos
Figure 3. Expression of endogenous GARS in cultured cells. A, B, D, E, G, H, J, K, Differentiated human SH-SY5Y cells were
stainedwith anti-GARS 673 (A,D,G, J ), anti--tubulin (B), anti-SMN (E), anti-nucleolar antigen (H ), anti-OxPhos complex IV (K ),
and DAPI and examined by confocal fluorescence microscopy. C, F, I, L, Merged images depict large GARS-associated globules in
the nuclei (C, arrowheads) and granules in the neurite projections (C, arrows); distinct and separate localization of SMN gems (F,
arrows) and nuclear GARS-associated globules (F, arrowheads); multiple sites of colocalized GARS-associated globules and nucle-
oli in the nucleus (I, arrowheads); and distinct cytoplasmic GARS-associated granules (L, arrows) in the absence of mitochondrial
staining (L, arrowheads).M–O, COS7 cells were stained with anti-GARS 673 and DAPI in the absence (M ) or presence (N ) of the
transfected pDsRed2–Mito vector. The merged image (O) shows GARS-associated granules (arrows) distinct from the labeled
mitochondria.
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complex IV; and (2) COS7 cells trans-
fected with a construct expressing a
mitochondrial-targeting sequence tagged
withDiscosoma sp. red fluorescent protein
(DsRed). Both cell populations were then
stained with anti-GARS673 and DAPI, in
both cases revealing GARS-associated
granules distinct from the labeled mito-
chondria (Fig. 3J–O). Thus, the GARS-
associated granules do not appear to rep-
resent mitochondria. In similar studies
involving differentiated SH-SY5Y cells
stained with anti-Golgin-97, anti-GARS673,
and DAPI, we found that the GARS-
associated granules do not appear to repre-
sent the Golgi apparatus (data not shown).
Because a subset of aminoacyl-tRNA
synthetases reside in multisynthetase
complexes (MSCs) (thought to raise the
efficiency of tRNA charging) (Han et al.,
2003), we also tested whether the GARS-
associated granules represent such com-
plexes. Specifically, we examined whether
GARS-associated granules colocalize with
tRNA synthetases shown previously to re-
side within [MARS and glutaminyl-tRNA
synthetase (QARS)] or outside of [seryl-
tRNA synthetase (SARS)] such multisyn-
thetase complexes (Han et al., 2003). This
involved transfecting SH-SY5Y cells with
vectors expressingMARS, QARS, or SARS
tagged with DsRed and staining the cells
with anti-GARS673, followed by confocal
microscopic analysis. In no case did we find
evidence for the colocalizationof theGARS-
associated granules and other aminoacyl-
tRNA synthetases (data not shown).
GARS localizes to peripheral nerve
axons in vivo
We also investigated the location of the
GARS protein in human neuronal tissue.
Human thoracic spinal cord and sural
nerve tissue sections (derived from pre-
sumably normal adult cadavers) were
stained with anti-human neurofilament,
anti-GARS673, and DAPI. These studies
revealed strong anti-GARS673 staining in
both the ventral (Fig. 4A–C) and dorsal
(Fig. 5A–C) horns of the spinal cord. In addition, axons of the
ventral (Fig. 4G–I) and dorsal (Fig. 5D–F) roots showed strong
anti-GARS673 staining, indicating thatGARS is present outside of
the neuronal cell body. Closer examination revealed that GARS is
associated with distinct granules in the axons of the ventral horn
(Fig. 4D–F), dorsal horn (data not shown), ventral root (Fig.
4 J–L), dorsal root (Fig. 5G–I), and sural nerve (Fig. 5J–L). Fi-
nally, anti-GARS673 staining was also seen in the nuclei of cells in
all of the above structures (Fig. 5 I,L, and data not shown).
Most mutant forms of GARS are mislocalized in cultured
motor neuron cells
The mouse motor neuron cell line MN-1 (Salazar-Grueso et al.,
1991) can be differentiated with GDNF and GFR-1 (Paratcha et
al., 2001). During differentiation, long neurite projections form,
providing an in vitromodel of nerve cell axons. To determine the
effect of GARS mutations on cellular localization, we transfected
MN-1 cells with expression vectors containing wild-type or mu-
tant GARS tagged with EGFP; the resulting cell populations were
then differentiated with GDNF and GFR-1 and examined by
fluorescence microscopy.
Wild-type GARS–EGFP associates with granules in both the
cell body and neurite projections of 42% of EGFP-positiveMN-1
cells (Fig. 6A–D,G). In contrast, L129P GARS–EGFP (Fig. 6E),
G240R GARS–EGFP (Fig. 6F), and EGFP alone (Fig. 6G) never
associatewith such granules, whereas E71GGARS–EGFP,H418R
GARS–EGFP, and G526R GARS–EGFP associate with these
granules in 36, 1, and 20% of EGFP-positive cells, respectively
Figure 4. Localization of GARS in the ventral horn and ventral root. A, B, D, E, G, H, J, K, Human thoracic spinal-cord sections
were stained with anti-GARS 673 (A, D, G, J ), anti-neurofilament (anti-NF; B, E, H, K ), and DAPI and examined by confocal
fluorescencemicroscopy. C, F, I, L, Merged images show strong GARS staining in the ventral horn (C), GARS-associated granules in
ventral horn axons (F, arrows), strong GARS staining in ventral root axons (I ), and GARS-associated granules in ventral root axons
(L, arrows).
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(Fig. 6G). Similar results were seen when these constructs were
transfected into human endothelial kidney 293T cells (data not
shown). Thus, four of the five GARSmutations studied give rise
to a markedly different protein localization pattern compared
with the wild-type enzyme.
Discussion
Our previous identification of GARS as the gene mutated in
CMT2D and dSMA-V (Antonellis et al., 2003) was somewhat
unexpected, because the encoded protein (GARS) is ubiquitously
expressed and plays a global role in protein synthesis. Under-
standing howGARSmutations lead to the highly specific pheno-
typic features of these peripheral neuropathies (Christodoulou et
al., 1995; Ionasescu et al., 1996; Sambuughin et al., 1998; An-
tonellis et al., 2003; Sivakumar et al., 2005) requires additional
insight about the mutant forms of GARS
found in affected individuals. Here, we
present studies examining the functional
consequences of GARS mutations as well
as some natural characteristics of GARS
that reveal important clues about the mo-
lecular pathology of these inherited
diseases.
A common pathological mechanism
for genetic disorders is a loss of function
through altered mRNA or protein levels,
although this is unusual for neurodegen-
erative diseases inherited in an autosomal
dominant manner. Based on several stud-
ies (Fig. 1), there does not appear to be
evidence for severely altered transcription,
translation, or protein stability associated
with the G240R GARS mutation (the one
for which lymphoblastoid cell lines are
available). However, our studies did not
examine GARS expression in neurons or
the effects of otherGARSmutations. Such
studies should be performed before defin-
itively concluding that CMT2D and
dSMA-Vdonot arise fromaltered levels of
GARS.
Modeling human GARS mutations in
the yeast ortholog (GRS1) revealed that
several mutations (L129P, H418R, and
G526R) do not complement removal of
wild-type GRS1, whereas others (E71G
andG240R) appear to do so. Interestingly,
L129P, H418R, and G526R are associated
only with dSMA-V, whereas E71G is asso-
ciated with either CMT2D or dSMA-V,
and G240R is only associated with
CMT2D. Thus, mutations showing a loss
of function in yeast are most closely asso-
ciatedwith dSMA-V (but notCMT2D). In
light of the phenotypic similarity of
CMT2D and dSMA-V, one explanation is
that all mutations cause a loss of function,
but that only those associated with
dSMA-V are severe enough to detect a
phenotype in yeast. Interestingly, two
GARS mutations have been associated
with both CMT2D and dSMA-V (Sam-
buughin et al., 1998; Antonellis et al.,
2003; Del Bo et al., 2006). Thus, if the
above speculation is correct, there are perhapsmodifiers ofGARS
mutations that promote development of either the CMT2D or
dSMA-V phenotype. Identifying such modifiers might aid diag-
nosis and understanding the molecular basis of these diseases.
Our yeast studies did not detect a dominant-negative effect of
GRS1mutations. This is surprising because GARS is predicted to
exist as a homodimer (Freist et al., 1996), and analogous yeast-
modeling studies of disease-causing mutations in the YARS gene
indicated such a dominant-negative effect in another variant of
CMT (Jordanova et al., 2006). Perhaps yeast assays are not sensi-
tive enough to detect a dominant-negative effect of GARSmuta-
tions. However, there are a number of possibilities that could
explain the molecular pathology of GARSmutations that do not
involve a dominant-negative effect on the homodimer. First, the
Figure5. LocalizationofGARS in thedorsal horn, dorsal root, and sural nerve.Human thoracic spinal cord (A–I ) and sural nerve
(J–L) sections were stained with anti-GARS 673 (A, D, G, J ), anti-neurofilament (anti-NF; B, E, H, K ), and DAPI and examined by
confocal fluorescencemicroscopy.Merged images show strongGARS staining in the dorsal horn (C), strongGARS staining in dorsal
root axons (F ), and GARS-associated granules in dorsal root (I, arrows) and sural nerve (L, arrows) axons. Note that GARS staining
can also be seen in nuclei of the dorsal root and sural nerve (I, L, arrowheads).
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peripheral neuropathy seen in dSMA-V and CMT2D may be
caused by haploinsufficiency of GARS (i.e., a 50% reduction in
protein function). This seems less likely because haploinsuffi-
ciency is rarely associated with autosomal dominant neurode-
generative diseases. Nonetheless, it is intriguing to consider that
very long axons may be particularly susceptible to a 50% reduc-
tion in the activity of certain enzymes that are required locally.
Second, GARS mutations may cause a transdominant negative
effect that alters another aspect of enzyme function. For example,
theymay impair the function of amultienzyme complex (such as
theGARS-associated granules). Finally, the observed loss of func-
tion described here for GARS mutations may not be the true
cause of the peripheral neuropathy (see below).
Protein-localization studies involving a mouse neuronal cell
line provided insight about the aggregation and cellular distribu-
tion of wild-type and mutant forms of GARS. Specifically, these
studies showed that wild-type GARS is associated with granules
in the cell body and neurite projections, whereas the majority of
the mutant forms of GARS are not. Two interesting consider-
ations arise from these findings. First, the altered cellular distri-
bution of mutant GARS may promote aberrant protein aggrega-
tion, possibly in a neuron-specific manner. Thus, whereas our in
vitro cell-culture assays did not detect aggregation ofmutant pro-
teins, GARS aggregation may occur in vivo, leading to impaired
axonal transport (or function) and the pathological axonopathy.
The identification of GARS-associated granules within axons is
consistent with this notion. Such a gain-of-function mechanism
is thought to underlie many neurodegenerative diseases (Wood
et al., 2003) and needs to be fully explored before any definitive
conclusions are made about the molecular pathology of CMT2D
and dSMA-V.
However, this redistribution of the mutant protein is consis-
tent with a loss-of-function mechanism. Thus, between the yeast
studies and the examination of GARS-associated granules in a
neuronal cell line, all GARS mutations except E71G show evi-
dence of a loss-of-function mechanism (Table 2). E71G may
cause a loss of GARS function that is not detectable as an effect on
yeast growth or on protein distribution in cell culture. Two ex-
perimental approaches can be envisioned to investigate this fur-
ther. First, the in vitro biochemical activity of the differentmutant
forms of GARS could be assayed to assess the tRNA-charging
capacity of each. Second,mRNAandprotein levels could be stud-
ied in cell lines from a patient harboring the E71G mutation to
look for impaired transcription or translation; however, no such
cell lines are available at the present time.
The identification of GARS-associated cytoplasmic granules
and nuclear globules is a novel finding and raises immediate
questions about their functional role(s). For proper protein
translation in eukaryotic cells, tRNA molecules must be charged
in both the cytoplasm andmitochondria. For some tRNA species,
a single aminoacyl-tRNA synthetase is responsible for both cyto-
plasmic and mitochondrial charging, whereas for others, there
are separate enzymes. GARS is thought to aminoacylate tRNAGly
molecules in both locations (Shiba et al., 1994; Turner et al.,
2000). Furthermore, aminoacyl-tRNA synthetases form cyto-
plasmicMSCs thought to enhance aminoacylation efficiency and
composed of at least eight aminoacyl-tRNA synthetases and the
nonenzyme anchor proteins p18, p38, and p48 (Han et al., 2003).
Thus, the cytoplasmic GARS-associated granules could poten-
tially represent mitochondria or MSCs. However, the results re-
ported here (Fig. 3) indicate that the GARS-associated granules
represent neither mitochondria or MSCs, suggesting that they
represent a previously unidentified structure. Our studies also
indicate that GARS localizes to the nucleolus in cultured cells.
Interestingly, methionyl-tRNA synthetase has been localized to
the nucleolus and is predicted to play a role in ribosomal RNA
biogenesis (Ko et al., 2000). Determining the role of GARS in
the nucleolus and cytoplasmic granules is of interest and will
likely be important for understanding dSMA-V and CMT2D
pathogenesis.
GARS missense mutations give rise to an axonal peripheral
neuropathy. If, indeed, these mutations act via a loss-of-function
mechanism, then there must be a unique role for GARS in pe-
ripheral nerve axons (in light of the limited phenotype of
Figure 6. Expression of wild-type and mutant GARS–EGFP in mouse motor neuron cells. A,
C, E, F, Differentiated MN-1 cells expressing wild-type (Wt) GARS–EGFP (A, C), L129P GARS–
EGFP (E), or G240R GARS–EGFP (F ) were examined by fluorescence microscopy. Wild-type
GARS–EGFP-associated granules within the cell body and neurite projections are indicated by
arrowheads and arrows, respectively. B, D, Merged images from fluorescence and differential
interference contrast microscopy reveal cell morphology and neurite-projection paths of cells
expressing wild-type GARS–EGFP. G, The percentage of EGFP-positive cells containing GARS-
associated granules was determined after transfection with constructs expressing wild-type
GARS–EGFP, the indicated mutant forms of GARS–EGFP, or EGFP alone. Five replicate experi-
ments consistently gave the observed results.
Table 2. Summary of functional studies of GARSmutations
GARSmutation Human phenotype Yeast viabilitya Granule formationb
Wild type None  Yes
E71G CMT2D or dSMA-V  Yes
L129P dSMA-V / Impaired
G240R CMT2D  Impaired
H418R dSMA-V  Impaired
G526R dSMA-V  Yesc
a, Normal viability;/, severely impaired growth, but not lethal;, lethal.
bGranule formation as detected in transfected MN-1 (Fig. 6) and 293T cells.
cGranule formation present but reduced.
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dSMA-V and CMT2D and the ubiquitous requirement of GARS
in all cells). We believe that our identification of GARS-
associated granules in vivo, which is the first report of a human
aminoacyl-tRNA synthetase localizing to axons, provides a clue
about such a unique role. Perhaps the GARS-associated granules
facilitate local tRNA charging and translation. Indeed, local pro-
tein synthesis in axons has been suggested by the identification of
translational activity and ribosomes in isolated mammalian axo-
plasm, tRNAs and aminoacyl-tRNA synthetases in squid axo-
plasm, and mRNA in the axoplasm of multiple vertebrates (Giu-
ditta et al., 2002). Therefore, GARS may be needed in axons to
charge recycled tRNAGly molecules and support local protein
synthesis, with its absence or dysfunction leading to CMT2D or
dSMA-V. Our cell culture studies suggest that GARS mutations
can abrogate the association of the GARS protein with granules.
This raises the possibility that the proper localization of GARS
within granules and the subsequent transport of the granules to
the periphery are essential for maintaining axonal health; in es-
sence, this would represent a special requirement for GARS in
peripheral nerve cell axons.
The recent finding that mutations in YARS cause dominant
intermediate CMT (Jordanova et al., 2006), a peripheral neurop-
athy with both demyelinating and axonal features, is relevant to
the studies reported here. Specifically, the association between
peripheral neuropathy and mutations in two genes with an im-
portant role in protein synthesis indicates that peripheral nerves
are uniquely susceptible to impaired or altered protein synthesis.
Furthermore, impaired degradation of a protein essential for as-
sembly of the multiple tRNA synthetase complex [p38/JTV1
(Kim et al., 2002; Corti et al., 2003; Ko et al., 2005)] is associated
with neurodegeneration in certain patients with Parkinson’s dis-
ease, indicating that neurons in general may be more susceptible
to protein synthesis defects.
Based on our studies, we propose that the peripheral neurop-
athy in CMT2D and dSMA-V is caused by impaired GARS en-
zyme activity, a GARS-localization defect, or a combination of
both. Perhaps a fundamental aspect of these diseases is the level of
functional GARS present in peripheral nerve axons. Individuals
with two wild-type GARS alleles presumably have 100% func-
tional GARS in the cell bodies of peripheral neurons, with a sub-
population ofGARS then transported to the periphery to support
axonal tRNAGly charging. GARS-mutation carriers likely have
decreased GARS activity levels, perhaps falling below some criti-
cal (and unique) threshold in the axon that leads to defective
axonal translation and axonal damage. Such a hypothesis is con-
sistent with the progressive nature of the disease as well as its
peripheral axon-specific pathology. Furthermore, non-neuronal
cells, neuron cell bodies, and axons spanning shorter distances
may be less sensitive to decreased GARS activity levels. Future
studies that further test this hypothesis and examine possible
gain-of-function mechanisms should provide more detailed in-
sight into the etiology of CMT2D and dSMA-V as well as the role
of tRNA-charging enzymes in maintaining healthy peripheral
axons.
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